Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial
- 28 August 2013
- journal article
- research article
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 25 (3) , 207-212
Abstract
Changes in body fat distribution and bone mass in HIV-infected patients may be associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs). The Monarch trial recruited 30 patients receiving non-nucleoside reverse transcriptase inhibitor or protease inhibitor−based highly active antiretroviral therapy, with HIV RNA p = 0.261) with no significant difference between arms (p = 0.56). There was a significant reduction in insulin resistance (HOMA-IR, p = 0.013) over 48 weeks in the whole group, but not of body mass index (p = 0.24). In the darunavir/ritonavir monotherapy arm, there was a small but significant increase in both lumbar and femur bone mineral density at 48 weeks and was observed after correction for baseline values. The absolute change in lumbar bone mineral density at 48 weeks was more pronounced in the darunavir/ritonavir arm compared with the darunavir/ritonavir + 2NRTIs arm. In this study, discontinuing nucleoside analogues and switching to darunavir/ritonavir monotherapy was associated with a small but statistically significant increase in bone mineral density, but stable levels of limb fat and visceral adipose tissue.Keywords
This publication has 20 references indexed in Scilit:
- Assessing AdiposityCirculation, 2011
- HIV and the body: a review of multidisciplinary managementHIV Medicine, 2010
- Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjectsAtherosclerosis, 2010
- Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week TrialClinical Infectious Diseases, 2009
- Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatmentAIDS, 2009
- General and Abdominal Adiposity and Risk of Death in EuropeNew England Journal of Medicine, 2008
- Contribution of Metabolic and Anthropometric Abnormalities to Cardiovascular Disease Risk FactorsCirculation, 2008
- Severity of Lipodystrophy Is Associated with Decreased Health-Related Quality of LifeAIDS Patient Care and STDs, 2008
- Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophyAIDS, 2006